Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SHR-A2102 for Injection plus other antitumor therapies in advanced solid tumors
CTR20251055Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102 in Nonhematologic neoplasms, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Apr 2025; status: active.
02
Drugs
SHR-A2102
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251055.